The influence of CYP2C19 polymorphisms on clinical efficacy of clopidogrel in Sudanese patients undergoing percutaneous coronary intervention
DOI:
https://doi.org/10.56511/JIPBS.2022.v9.i02.pp30-35Abstract
Clopidogrel is commonly used anti-platelet drugs in treatment of patients undergoing percutaneous coronary intervention (PCI). It was documented that CYP2C19 loss of function variants may affect clopidogrel efficacy and exposed patients to risk of adverse cardiac events. This study aimed to appraise the link between CYP2C19 polymorphisms and adverse clinical outcomes in Sudanese patients undergoing PCI. This prospective observational cohort study recruited 197 PCI patients from Wad Medani Heart Diseases and Surgery Center from 2017 to 2021. The patients were distributed into three groups according to their genotype results as follow: Extensive metabolizers (EMs) 136, Intermediate metabolizers (IMs) 56, and Poor metabolizers (PMs) 5. All study cohort received aspirin and clopidogrel. Clinical ends points were evaluated after 12 months from PCI indexing by rechecking patients' records. The metabolizing capacity among the groups did not show significant relations to demographics and clinical characteristics (P>0.05), except that PMs showed a significantly higher mean body weight than IMs (P=0.010). Ischemic heart disease was significantly higher among PMs in comparison to IMs and EMs (60.0% versus 5.5% and 11.0% respectively, P=0.006). Previous angiography was also significantly more common among PMs in comparison to IMs and NMs (60.0% versus 8.9% and 9.6% respectively, P=0.013). The frequency of adverse cardiac events (ACEs) was higher among PMs in comparison to IMs and EMs (40% vs 16.1%, 10.3%), however no significant association found between ACEs and the metabolizer capacity (P=0.078). On the other hand, revascularization was significantly related to the metabolizer capacity, where 40.0% of PMs developed revascularization compared to 7.1% in IMs and 4.4% in EMs (P=0.029). The risk of revascularization was 14.44 (2.019-103.317) in PMs and 1.67 (0.452-6.149) in IMs. In conclusion ACEs was more prevalent among PMs in comparison to IMs and EMs. Moreover, revascularization was significantly higher among PMs in comparison to IMs and EMs.
Keywords:
Clopidogrel, Percutaneous coronary intervention, CYP2C19 polymorphism, Adverse cardiac eventsDownloads
References
Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G. and Fox K.K. : Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST - segment elevation . New England Journal of Medicine. 2001 ; 345(7):494 - 502.
Steinhubl SR, Berger PB, Mann III JT, Fry ET, DeLago A, Wilmer C, Topol EJ, Credo Investigators, CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized con trolled trial. Jama. 2002 ; 288(19):2411 - 20.
Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht HJ, Zhao F, Chrolavicius S, Copland I. Effects of pretreatment with clopidogrel and aspirin followed by long - term therapy in patients undergoing percutaneous coronary intervention: the PCI - CUR E study. The Lancet. 2001 ; 358 (9281):527 - 33.
Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, Regar E, McFadden EP, Sianos G, van der Giessen WJ, de Jaegere PP. Thirty - day incidence and six - month clinical outcome of thrombotic stent occlusion after bare - metal, sirolimus, or paclitaxel stent implantation. Journal of the American Co llege of Cardiology. 2005 ; 45(6):947 - 53.
Cuisset T, Quilici J, Grosdidier C, Fourcade L, Gaborit B, Pankert M, Molines L, Morange PE, Bonnet JL, Alessi MC. Comparison of platelet reactivity and clopidogrel response in patients≤ 75 years versus> 75 years undergoing percutaneous coronary intervention for non – ST - segment elevation acute coronary syndrome. The American jo urnal of cardiology. 2011 ; 108(10):1411 - 6.
Hochholzer W, Trenk D, Fromm MF, Valina CM, Stratz C, Bestehorn HP, Büttner HJ, Neumann FJ. Impact of cytochrome P450 2C19 loss - of - function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. Journal of the American College of Cardiology. 2010; 55(22):2427 - 34.
Khalil BM, Shahin MH, Solayman MH, Langaee T, Schaalan MF, Gong Y, Hammad LN, Al ‐ Mesallamy HO, Hamdy NM, El ‐ Hammady WA, Johnson JA. Genetic and nongenetic factors affecting clopidogrel response in the Egyptian population. Clinical and translational science. 2016; 9(1):23 - 8.
Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH. Meta - analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. The American journal of cardiology. 2012; 110(4):502 - 8.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD. Reduced - function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for P CI: a meta - analysis. Jama. 2010 ; 304(16):1821 - 30.
Amin AM, Sheau Chin L, Azri Mohamed Noor D, SK Abdul Kader MA, Kah Hay Y, Ibrahim B. The personalization of clopidogrel antiplatelet therapy: the role of integrative pharmacogenetics and pharmacometabolomics. Cardiology research and practice. 2017 ; 2017.
Pereira NL, Geske JB, Mayr M, Shah SH, Rihal CS. Pharmacogenetics of clopidogrel: an unresolved issue. Circulation: C ardiovascular Genetics. 2016 ; 9(2):185 - 8.
Wei Y, Wang D, Yang H, Cao H. Cytochrome P450 CYP 2C19*2 associated with adverse 1 - year cardiovascular events in patients with acute coronary syndrome. PLoS One. 2015; 10(7):e0132561.
Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, Lachno DR, Salazar D, Winters KJ. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thro mbosis and Haemostasis. 2007 ; 5(12):2429 - 36.
Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, Ikeda T, Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metabolism and Dispositi on. 2010 ; 38(1):92 - 9.
Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain - Appaix A, Vignalou JB, Galier S. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS - 2 (Clopidogrel and Response Variability Investigation Study 2). JACC: Cardiovascular Interventions. 2011; 4(4):392 - 402.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p - 450 polymorphisms and response to clopidogrel. New England journal of medicine. 2009; 360(4):354 - 62.
Simon T, Verstuyft C, Mary - Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L. Genetic determinants of response to clopidogrel and cardiovascular events. New England journal of medicine. 2009; 360(4):363 - 75.
Chan MY. Clopidogrel pharmacogenetics of east, south and other Asian populations. European Heart Journal Supplements. 2012; 14(suppl_A):A41 - 2.
Brown SA, Pereira N. Pharmacogenomic impact of CYP2C19 variation on clopidogrel therapy in precision cardiovascular medicine. Journal of personal ized medicine. 2018; 8(1):8.
Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, Simonsen K, Bhatt DL, Fox KA, Eikelboom JW. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. New England Journal of Medicine. 2010; 363(18):1704 - 14.
Siller - Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, Jilma B. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta - analysis. Heart. 2011; 97(2):98 - 105.
Ernest CS, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin - treated patients with stable coronary artery disease. Journal of pharmacokinetic s and pharmacodynamics. 2008 ; 35(6):593 - 618.
Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P. Double - dose versus standard - dose clopidogrel and high - dose versus low - dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT - OASIS 7): a randomised factorial trial. The Lancet. 2010; 376(9748):1233 - 43.
Hao PP, Zhang MX, Li RJ, Yang JM, Wang JL, Chen YG, Zhang Y. Clopidogrel 150 vs. 75 mg day− 1 in patients undergoing percutaneous coronary intervention: a meta ‐ analysis. Journal of Thrombosis and H aemostasis. 2011; 9(4):627 - 37.
Wang ZY, Chen M, Zhu LL, Yu LS, Zeng S, Xiang MX, Zhou Q. Pharmacokinetic drug interactions with clopidogrel: updated review and risk management in combination therapy. Therapeutics and clinical risk management. 2015; 11:449.
Chen XP, Tan ZR, Huang SL, Huang Z, Ou ‐ Yang DS, Zhou HH. Isozyme ‐ specific induction of low ‐ dose aspirin on cytochrome P450 in healthy subjects. Clinical Pharmacology & Therapeutics. 2003; 73(3):264 - 71.
Oh J, Shin D, Lim KS, Lee S, Jung KH, Chu K, Hong KS, Shin KH, Cho JY, Yoon SH, Ji SC. Aspirin decreases systemic exposure to clopidogrel through modulation of P ‐ glycoprotein but does not alter its antithrombotic activity. Clinical Pharm acology & Therapeutics. 2014 ; 95(6):608 - 16.
Jaichander P, Selvarajan K, Garelnabi M, Parthasarathy S. Induction of paraoxonase 1 and apolipoprotein AI gene expression by aspirin. Jou rnal of lipid research. 2008 ; 49(10):2142 - 8.
Bouman HJ, Schömig E, Van Werkum JW, Velder J, Hackeng CM, Hirschhäuser C, Waldmann C, Schmalz HG, Ten Berg JM, Taubert D. Paraoxonase - 1 is a major determinant of clopidogrel eff icacy. Nature medicine. 2011 ; 17(1):110 - 6.
Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P. Cytochrome P450 2C19 loss - of - function polymorphism is a major determinant of clopidogrel responsiveness in hea lthy subjects. Blood. 2006 ; 108(7):2244 - 7.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD. Reduced - function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta - analysis. Jama. 2010; 304(16):1821 - 30.
Hulot JS, Collet JP, Silvain J, Pena A, Bellemain - Appaix A, Barthélémy O, Cayla G, Beygui F, Montalescot G. Cardiovascular risk in clopidogrel - treated patients according to cytochrome P450 2C19* 2 loss - of - function allele or proton pump inhibitor coadministration: a systematic meta - analysis. Journal of the American College of Cardiology. 2010; 56(2):134 - 43.
Shuldiner AR, O’Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, Pollin TI. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Jama. 2009; 302(8):849 - 57.
Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta - analysis. Jama. 2011; 306(24):2704 - 14.
Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD. Reduced - function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta - analysis. Jama. 2010; 304(16):1821 - 30.
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European heart journal. 2012; 33(17):2143 - 50.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Tahani Hassan Ibrahim, Imad Eldin Mohamed Tag Eldin, Abd Elwahab Hassan Mohamed, Ameer Mohamed Dafalla, Abdalla Karem Gibreel, Adil Mergani
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at